[Corrections] Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4

Di |2024-06-28T00:30:01+02:00Giugno 28th, 2024|Categorie: Coronavirus Lancet|

Chang CC, Harrison TS, Bicanic TA, et al. Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM. Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S147...

[Correspondence] Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities

Di |2024-06-21T00:30:01+02:00Giugno 21st, 2024|Categorie: Coronavirus Lancet|

In the 2024 study by Ann R Falsy and colleagues, the Ad26.RSV.preF–RSV preF protein vaccine offered strong protection against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in healthy adults aged 65 years or older (84·1%) and ...

[Corrections] Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4

Di |2024-06-15T00:30:01+02:00Giugno 15th, 2024|Categorie: Coronavirus Lancet|

Dattwyler RJ, Arnaboldi PM. Vaccination hesistancy in Lyme borreliosis. Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4—In this Comment, the declaration of interests has been updated. This correction has b...

[Articles] Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Di |2024-06-14T00:30:06+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The RH5.1/Matrix-M vaccine candidate shows an acceptable safety and reactogenicity profile in both adults and 5–17-month-old children residing in a malaria-endemic area, with all children in the delayed third dose regimen reaching a level of GIA previo...

[Articles] Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study

Di |2024-06-14T00:30:02+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

The high treatment success and good safety results indicate considerable potential for the use of mSTRs in programmatic conditions, especially for individuals not eligible for the current WHO-recommended 6-month regimen and in settings with a need for ...

[Comment] Longevity of modified standard short treatment regimens for rifampicin-resistant tuberculosis

Di |2024-06-14T00:30:01+02:00Giugno 14th, 2024|Categorie: Coronavirus Lancet|

Yearly, about 410 000 patients worldwide develop rifampicin-resistant tuberculosis, resistant to the most powerful first-line tuberculosis drug. In 2012, treatment for rifampicin-resistant tuberculosis constituted mainly regimens of 18 months or longer...

[Correspondence] Survival analysis of patients with cholera admitted to treatment centres in Lusaka, Zambia

Di |2024-06-13T00:30:01+02:00Giugno 13th, 2024|Categorie: Coronavirus Lancet|

Cholera remains a global threat to health security, particularly in sub-Saharan Africa where outbreaks have become frequent, with increased magnitude and fatalities.1,2 While the world is preparing for the next pandemic, we explored clinical outcomes a...

Torna in cima